Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI

27.06.2003


A group of scientists from The Scripps Research Institute (TSRI) and several other institutions has solved the structure of an antibody that effectively neutralizes human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).



The antibody binds to sugars on the surface of HIV and effectively neutralizes the virus because of its unique structure, which is described in the latest issue of the journal Science.

"What we found was an unusual configuration of the antibody in which its two Fab domains -- the antigen recognition units -- are ’interdigitating’ with each other," says TSRI Professor Ian Wilson, D.Phil., one of two TSRI professors who led the research. "Nothing like this has ever been seen before."


This new structure is an important step toward the goal of designing an effective vaccine against HIV, and it gives the researchers a new way to design antibodies in general.

"It may enable us to make antibodies that recognize whole new sets of molecules," says TSRI Professor Dennis Burton, Ph.D., the other TSRI professor who led the research.

The Problem of HIV and Antibodies

HIV causes AIDS by binding to, entering and ultimately, killing T helper cells, immune cells that are necessary to fight off infections by common bacteria and other pathogens. As HIV depletes the body of T helper cells, common pathogens can become potentially lethal.

The latest statistics are grim. The World Health Organization estimates that around 40 million people are living with HIV worldwide. During 2001 alone, more than four million men, women, and children succumbed to the disease, and by the end of that year, the disease had made orphans of 14 million children. In the United States, 40,000 people are infected with HIV each year.

One of the most compelling medical challenges today is to develop a vaccine that will provide complete prophylactic protection to someone who is later exposed to this virus. An important part of such a vaccine will be a component that elicits or induces effective neutralizing antibodies against HIV in the blood of the vaccinated person.

Also called immunoglobins, antibodies are the basis for many existing vaccines, including those against measles, polio, hepatitis B, and hepatitis A. HIV antibodies are produced by the body’s B cells after HIV enters the bloodstream. During such an immune response, the antibodies circulate through the blood. Good antibodies bind to and "neutralize" the virus, making it unable to invade cells. Because neutralizing antibodies attack the virus before it enters cells, they could conceivably be used to prevent HIV infection if they were present prior to virus exposure. A vaccine would seek to elicit these neutralizing antibodies.

This is easier said than done. The body makes lots of antibodies against HIV, but they are almost always unable to neutralize the virus. Much of the viral surface is coated with carbohydrates (sugars), which are hard for the immune system to attack because these sugars are made by human cells and attached by human proteins. In other words, they are "self" and should not be recognized by antibodies.

However, in rare instances some people have produced antibodies that broadly neutralize HIV. One such antibody, called 2G12, was isolated from an HIV-positive individual about a decade ago by Hermann Katinger, a doctor at the Institute for Applied Microbiology of the University of Agriculture in Vienna, Austria and one of the authors on the paper. This antibody is not like ordinary antibodies.

"The Fab [antigen recognition] arms are interlocked," says Burton. "That is a unique arrangement, and it is good for recognizing a cluster of shapes like sugars on a virus."

The 2G12 antibody forms an unusual "dimer" interface where two antibodies create an unusual multivalent binding interface with multiple binding sites that recognizes an unusual arrangement of 2-3 "oligomannose" sugars on the surface of protein spikes called gp120 that decorate the coat of HIV. This allows the antibody to properly target HIV virions as foreign pathogens. The sugars are human but their arrangement is foreign-and it is this arrangement that the antibodies recognize.

These results are a step in the direction of designing an effective AIDS vaccine because it reveals what these neutralizing antibodies should look like. The next step is to use the structure of the antibody as a template to design an "antigen" that would stimulate the human immune system to make 2G12 or similar broadly neutralizing antibodies against HIV.

The results are also important because the structure of the antibody is something that has never been seen before. "Can we now," asks Wilson, "use this [knowledge] to engineer antibodies with higher affinity against other antigens or clusters of antigens?"



The TSRI study combined experts from several institutions besides TSRI, including Pauline M. Rudd, Ph.D., and Raymond A. Dwek, D.Phil., D.Sc., FRS, from the Glycobiology Institute at Oxford University in the United Kingdom. Also involved in the study were researchers in the Department of Biological Science and Structural Biology at Florida State University in Tallahassee.

The research article, "Antibody Domain Exchange is an Immunological Solution to Carbohydrate Cluster Recognition" is authored by Daniel A. Calarese, Christopher N. Scanlan, Michael B. Zwick, Songpon Deechongkit, Yusuke Mimura, Renate Kunert, Ping Zhu, Mark R.Wormald, Robyn L. Stanfield, Kenneth H. Roux, Jeffery W. Kelly, Pauline M. Rudd, Raymond A. Dwek, Hermann Katinger, Dennis R. Burton, and Ian A. Wilson and appears in the June 27, 2003 issue of the journal Science.

The research was supported by The Skaggs Institute for Research, which funds The Skaggs Institute for Chemical Biology at TSRI. TSRI is one of the world’s largest, private, non-profit biomedical research organizations and is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases and synthetic vaccine development. It is dedicated to the creation of basic knowledge in the biosciences for medical application and the betterment of human health, to the pursuit of fundamental scientific advances through interdisciplinary programs and collaborations, and to the education and training of researchers from around the world preparing to meet the scientific challenges of the future.

Grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS) also supported this research. NIGMS is part of the National Institutes of Health (NIH), U.S. Department of Health and Human Services and supports basic biomedical research that lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS also trains tomorrow’s scientists and makes special efforts to increase the number of minority researchers. A component of the NIH, NIAID conducts and supports research that strives to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten hundreds of millions of people worldwide. NIAID’s mission is driven by a strong commitment to basic research and the understanding that the fields of immunology, microbiology, and infectious disease are related and complementary.

The research is further supported by the International AIDS Vaccine Initiative (IAVI). Burton and Wilson are part of the multi-million-dollar Neutralizing Antibody Consortium launched last year by IAVI, a global nonprofit organization working to speed scientific progress toward developing safe and effective vaccines to prevent HIV/AIDS that will be accessible worldwide. IAVI’s work focuses on four areas: mobilizing support through advocacy and education, accelerating scientific progress, encouraging industrial participation in AIDS vaccine development, and assuring global access. Burton is the director of the Neutralizing Antibody Consortium.

Jason Bardi | EurekAlert!
Further information:
http://www.scripps.edu/

More articles from Life Sciences:

nachricht Repairing damaged hearts with self-healing heart cells
22.08.2017 | National University Health System

nachricht Biochemical 'fingerprints' reveal diabetes progression
22.08.2017 | Umea University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Cholesterol-lowering drugs may fight infectious disease

22.08.2017 | Health and Medicine

Meter-sized single-crystal graphene growth becomes possible

22.08.2017 | Materials Sciences

Repairing damaged hearts with self-healing heart cells

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>